In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis

被引:32
|
作者
Hoban, DJ
Zhanel, GG
Karlowsky, JA
机构
[1] Hlth Sci Ctr, Dept Clin Microbiol, Winnipeg, MB R3A 1R9, Canada
[2] Hlth Sci Ctr, Dept Med, Winnipeg, MB R3A 1R9, Canada
[3] Univ Manitoba, Fac Med, Dept Med Microbiol, Winnipeg, MB, Canada
[4] Univ Manitoba, Fac Pharm, Winnipeg, MB R3T 2N2, Canada
关键词
D O I
10.1016/S0732-8893(99)00053-X
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The in vitro activities of HMR 3647, erythromycin A, clarithromycin, azithromycin, roxithromycin, penicillin G, ampicillin, cefuroxime, trimethoprim/sulfamethoxazole, tetracycline, ciprofloxacin, and levofloxacin were determined for 1179 Streptococcus pneumoniae, 1438 Haemophilus influenzae, and 428 Moraxella catarrhalis isolated from respiratory tract specimens by 18 medical centers across Canada during 1997-1998. On a per weight basis, HMR 3647 was the most active agent tested against S, pneumoniae with MIC(90)s of less than or equal to 0.12 mu g/mL for both penicillin susceptible and penicillin intermediate isolates and 0.25 mu g/mL for penicillin-resistant isolates. HMR 3647 was also highly active against M. catarrhalis (MIC(90), less than or equal to 0.12 mu g/mL), but less active against H. influenzae (MIC(90), 4 mu g/mL). (C) 1999 Elsevier Science Inc.
引用
下载
收藏
页码:37 / 44
页数:8
相关论文
共 50 条
  • [31] Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species
    Johnson, DM
    Biedenbach, DJ
    Beach, ML
    Pfaller, MA
    Jones, RN
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 37 (02) : 99 - 105
  • [32] In Vitro Antimicrobial Activity of Cefditoren against Streptococcus pneumoniae and Haemophilus influenzae Clinical Isolates
    Kim, Nam Joong
    Kim, Sung Hye
    Kim, Mi Young
    Jun, Jae Bum
    Park, Su Jin
    Kwak, Yee Gyung
    Jeong, Jin-Yong
    Choi, Sang-Ho
    Woo, Jun Hee
    Ryu, Jiso
    Kim, Yang Soo
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 26 : S83 - S83
  • [33] In vitro activities of the ketolides ABT-773 and telithromycin and of three macrolides against genetically characterized isolates of Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis
    Schmitz, FJ
    Schwarz, S
    Milatovic, D
    Verhoef, J
    Fluit, AC
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (01) : 145 - 148
  • [34] In vitro activity of telithromycin (HMR 3647) against Greek Streptococcus pyogenes and Streptococcus pneumoniae clinical isolates with different macrolide susceptibilities
    Ioannidou, S
    Tassios, PT
    Zachariadou, L
    Salem, Z
    Kanelopoulou, M
    Kanavaki, S
    Chronopoulou, G
    Petropoulou, N
    Foustoukou, M
    Pangalis, A
    Trikka-Graphakos, E
    Papafraggas, E
    Vatopoulos, AC
    CLINICAL MICROBIOLOGY AND INFECTION, 2003, 9 (07) : 704 - 707
  • [35] ANTIMICROBIAL RESISTANCE AMONG RESPIRATORY ISOLATES OF HAEMOPHILUS-INFLUENZAE, MORAXELLA-CATARRHALIS, AND STREPTOCOCCUS-PNEUMONIAE IN THE UNITED-STATES
    JORGENSEN, JH
    DOERN, GV
    MAHER, LA
    HOWELL, AW
    REDDING, JS
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (11) : 2075 - 2080
  • [36] In vitro pharmacodynamic activities of ABT-492, a novel quinolone, compared to those of Levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
    Gunderson, SM
    Hayes, RA
    Quinn, JP
    Danziger, LH
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (01) : 203 - 208
  • [37] ANTIBACTERIAL ACTIVITY OF CEFIXIME AGAINST STREPTOCOCCUS-PNEUMONIAE, STREPTOCOCCUS-PYOGENES, AND HAEMOPHILUS-INFLUENZAE IN THE PRESENCE OF MORAXELLA (BRANHAMELLA) CATARRHALIS
    YAMADA, T
    YOKOTA, Y
    IKEDA, F
    MINE, Y
    KITADA, T
    CHEMOTHERAPY, 1992, 38 (01) : 28 - 35
  • [38] Dynamics of Bacterial Colonization With Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis During Symptomatic and Asymptomatic Viral Upper Respiratory Tract Infection
    DeMuri, Gregory P.
    Gern, James E.
    Eickhoff, Jens C.
    Lynch, Susan V.
    Wald, Ellen R.
    CLINICAL INFECTIOUS DISEASES, 2018, 66 (07) : 1045 - 1053
  • [39] The incidence of respiratory tract pathogens and antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella (Branhamella) catarrhalis isolated between 1990 and 1993
    Nishioka, K
    Ogihara, H
    Ohno, I
    Tanno, Y
    Shirato, K
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 179 (02): : 111 - 121
  • [40] In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against and Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
    Brueggemann, AB
    Kugler, KC
    Doern, GV
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (07) : 1594 - 1597